Advances in strategies to improve drug delivery to brain tumors

Expert Review of Neurotherapeutics

Volumn 6, Issue 10, 2006, Pages 1495-1509

  Newton, Herbert B ^a  

^a Dardinger Neuro Oncology Center   (United States)

Author keywords

Antibodies; Blood brain barrier; Brain tumor; Drug delivery; Liposomes; Nanoparticles

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; DEXAMETHASONE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; DRUG CARRIER; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; EPIDERMAL GROWTH FACTOR; FLUOROURACIL; GANCICLOVIR; IMMUNOGLOBULIN; INSULIN RECEPTOR; INTERLEUKIN 2; IRINOTECAN; LIPOSOME; LOBRADIMIL; METHOTREXATE; MONOCLONAL ANTIBODY; NANOPARTICLE; NEUROTROPIN; PACLITAXEL; POLYMER; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; TEMOZOLOMIDE; THYMIDINE KINASE 1; TRANSFERRIN RECEPTOR; UNINDEXED DRUG;

BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHEMICAL MODIFICATION; CLINICAL TRIAL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG PENETRATION; DRUG TARGETING; DRUG TRANSPORT; GLYCOSYLATION; HUMAN; MOLECULAR MIMICRY; NONHUMAN; PEGYLATION; REVIEW; SUICIDE GENE THERAPY; THERMODYNAMICS; TRANSCYTOSIS;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS;

EID: 33750630071     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.10.1495     Document Type: Review

References (127)

1. Newton HB. Primary brain tumors: review of etiology, diagnosis, and treatment. Am. Fam. Phys. 49, 787-797 (1994).
2. Davis FG, McCarthy BJ. Current epidemiological trends and surveillance issues in brain tumors. Expert Rev. AntiCancer Ther. 1, 395-401 (2001).
3. Wrensch M, Minn Y, Chew T, Bondy M, Berger MS. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro-Oncol. 4, 278-299 (2002).
4. Kleihues P, Louis DN, Scheithauer BW et al. The WHO classification of tumors of the nervous system. J. Neuropathol. Exp. Neurol. 61, 215-225 (2002).
5. Newton HB. Neurological complications of systemic cancer. Am. Fam. Phys. 59, 878-886 (1999).
6. Legler JM, Ries LA, Smith MA et al. Cancer surveillance series: brain and other central nervous system cancers: recent trends in incidence and mortality. J. Natl Cancer Inst. 91, 1382-1390 (1999).
7. ACS (American Cancer Society): Cancer Facts and Figures 2002. American Cancer Society, GA, USA (2002).
8. Fine HA, Dear KBG, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71, 2585-2597 (1993).
9. Stewart LA, Burdett S, Parmar MKB et al. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomized trials. Lancet 359, 1011-1018 (2002).
10. Newton HB. Molecular neuro-oncology and the development of "targeted" therapeutic strategies for brain tumors. Part 1: growth factor and ras signaling pathways. Expert Rev. AntiCancer Ther. 3, 595-614 (2003). Thorough review.
11. Newton HB. Molecular neuro-oncology and the development of "targeted" therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH, and angiogenesis. Expert Rev. AntiCancer Ther. 4, 105-128 (2004). Thorough review.
12. Newton HB. Molecular neuro-oncology and the development of "targeted" therapeutic strategies for brain tumors. Part 5: apoptosis and cell cycle. Expert Rev. AntiCancer Ther. 5, 355-378 (2005). Thorough review.
13. Kesari S, Ramakrishna N, Sauvageot C, Stiles CD, Wen PY. Targeted molecular therapy of malignant gliomas. Curr. Oncol. Rep. 8, 58-70 (2006). Thorough review.
14. Reardon DA, Wen PY. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist 11, 152-164 (2006).
15. Ribatti D, Nico B, Crivellato E, Artico M. Development of the blood-brain barrier: a historical point of view. Anat. Rec. B New Anat. 289, 3-8 (2006).
16. Pardridge WM. Blood-brain barrier biology and methodology. J. Neurovirol. 5, 556-569 (1999).
17. Pardridge WM. Molecular biology of the blood-brain barrier. Mol. Biotechnol. 30, 57-70 (2005). Excellent review of blood-brain barrier (BBB) biology.
18. Shusta EV. Blood-brain barrier genomics, proteomics, and new transporter discovery. NeuroRx 2, 151-161 (2005).
19. Tsuji A, Tamai II. Carrier-mediated or specialized transport of drugs across the blood-brain barrier. Adv. Drug Deliv. Rev. 36, 277-290 (1999).
20. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 7, 41-53 (2006). Detailed review of astrocyte-endothelial interactions
21. Huber JD, Egleton RD, Davis TP. Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci. 24, 719-725 (2001).
22. Wolburg H, Lippoldt A. Tight junctions of the blood-brain barrier: development, composition, and regulation. Vascul. Pharmacol. 38, 223-337 (2002).
23. Feldman GJ, Mullin JM, Ryan MP. Occludin: structure, function, and regulation. Adv. Drug Deliv. Rev. 57, 883-917 (2005).
24. Van Itallie CM, Anderson JM. Claudins and epithelial paracellular transport. Ann. Rev. Physiol. 68, 403-429 (2006).
25. Bazzoni G. The JAM family of junctional adhesion molecules. Curr. Opin. Cell Biol. 15, 525-530 (2003).
26. Anderson JM, Fanning AS, Lapierre L, Van Itallie CM. Zonula occludens (ZO)-1 and ZO-2: membrane-associated guanylate kinase homologues (MAGuKs) of the tight junction. Biochem. Soc. Trans. 23, 470-475 (1995).
27. de Boer AG, van der Sandt ICJ, Gaillard PJ. The role of drug transporters at the blood-brain barrier. Ann. Rev. Pharmacol. Toxicol. 43, 629-656 (2003).
28. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl Cancer Inst. 92, 1295-1302 (2000).
29. Schlageter KE, Molnar P, Lapin GD, Groothuis DR. Microvesesel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties. Microvasc. Res. 58, 312-328 (1999).
30. Groothuis DR. The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro-oncol. 2, 45-59 (2000).
31. Parney IF, Prados MD. Chemotherapy principles. In: Textbook of Neuro-oncol.ogy. Berger MS, Prados MD (Eds). Elsevier Saunders, PA, USA 11, 75-79 (2005).
32. Pardridge WM. CNS drug design based on principles of blood-brain barrier transport. J. Neurochem. 70, 1781-1792 (1998).
33. Rapoport SI, Ohno K, Pettigrew KD. Drug entry into the brain. Brain Res. 172, 354-359 (1979).
34. Levin VA. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J. Med. Chem. 23, 682-684 (1980).
35. Blasberg RG, Groothuis DR. Chemotherapy of brain tumors: physiological and pharmacokinetic considerations. Semin. Oncol. 13, 70-82 (1986).
36. Diamond JM, Wright EM. Molecular forces governing non-electrolyte permeation through cell membranes. Proc. R. Soc. Lond., B, Biol. Sci. 171, 273-316 (1969).
37. Jain RK. Transport of molecules in the interstitium: a review. Cancer Res. 47, 3039-3051 (1987).
38. Stohrer M, Boucher Y, Stangassinger M, Jain RK. Oncotic pressure in solid tumors is elevated. Cancer Res. 60, 4251-4255 (2000).
39. Abbott NJ, Romero IA. Transporting therapeutics across the blood-brain barrier. Mol. Med. Today 2(3), 106-113 (1996).
40. Kroll RA, Neuwelt EA. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurg. 42, 1083-1100 (1998).
41. Pardridge WM. Brain drug targeting and gene technologies. Jpn. J. Pharmacol. 87, 97-103 (2001).
42. Pardridge WM. Drug and gene targeting to the brain with molecular Trojan horses. Nature Rev. Drug Discov. 1, 131-139 (2002). Detailed overview of vector-mediated delivery approaches.
43. Pardridge WM. Targeting neurotherapeutic agents through the blood-brain barrier. Arch. Neurol. 59, 35-40 (2002).
44. Demeule M, Régina A, Annabi B, Bertrand Y, Bojanowski MW, Béleveau R. Brain endothelial cells as pharmacological targets in brain tumors. Mol. Neurobiol. 30, 157-183 (2004).
45. McCarty JH. Cell biology of the neurovascular unit: implications for drug delivery across the blood-brain barrier. Assay Drugs Dev. Technol. 3, 89-95 (2005).
46. Egleton RD, Davis TP. Development of neuropeptide drugs that cross the blood-brain barrier. NeuroRx 2, 44-53 (2005).
47. Tsuji A. Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems. NeuroRx 2, 54-62 (2005). Excellent review of carriermediated transport.
48. Cucullo L, Aumayr B, Rapp E, Janigro D. Drug delivery and in vitro models of the blood-brain barrier. Curr. Opin. Drug Discov. Devel. 8, 89-99 (2005).
49. Chikhale EG, Ng KY, Burton PS, Borchardt RT. Hydrogen bonding potential as a determinant of the in vitro and in situ blood-brain permeability of peptides. Pharm. Res. 11, 412-419 (1994).
50. Poduslo JF, Curran GL. Glycation increases the permeability of proteins across the blood-nerve and blood-brain barriers. Brain Res. Mol. Brain Res. 23, 157-162 (1994).
51. Egleton RD, Mitchell SA, Huber JD et al. Improved bioavailability to the brain of glycosylated Met-enkephalin analogs. Brain Res. 881, 37-46 (2000).
52. Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly(ethyleneglycol)-protein conjugates. Adv. Drug Deliv. Rev. 26, 1261-1277 (2003).
53. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2, 214-221 (2003).
54. Morpurgo M, Veronese FM. Conjugates of peptides and proteins to polyethylene glycols. Methods Mol. Biol. 283, 45-70 (2004).
55. Pardridge WM, Wu D, Sakane T. Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotropic factor following intravenous administration. Pharm. Res. 15, 576-582 (1998).
56. Molineux G. Pegylation: engineering improved biopharmaceuticals for oncology. Pharmacother. 23, S3-S8 (2003).
57. Deguche Y, Kurihara A, Pardridge WM. Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker. Bioconjugate Chem. 10, 32-37 (1999).
58. Borlongan CV, Emerich DF. Facilitation of drug entry into the CNS via transient permeation of blood brain barrier: laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport. Brain Res. Bull. 60, 297-306 (2003).
59. Prados MD, Schold SC, Fine HA et al. A randomized, double-blind, placebo-controlled, Phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro-oncol. 5, 96-103 (2003).
60. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 47, 65-81 (2001).
61. Lockman PR, Mumper RJ, Khan MA, Allen DD. Nanoparticle technology for drug delivery across the blood-brain barier. Drug Dev. Ind. Pharm. 28, 1-13 (2002).
62. Olivier JC. Drug transport to brain with targeted nanoparticles. NeuroRx 2, 108-119 (2005).
63. Silva GA. Neuroscience nanotechnology: progress, opportunities, and challenges. Nature Rev. Neurosci. 7, 65-74 (2006).
64. Tiwari SB, Amiji MM. A review of nanocarrier-based CNS delivery systems. Curr. Drug Deliv. 3, 219-232 (2006). Detailed review of nanocarrier-based CNS delivery.
65. Gref R, Domb A, Quellec P et al. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv. Drug Deliv. Rev. 16, 215-233 (1995).
66. Jain KK. Nanotechnology-based drug delivery for cancer. Technol. Cancer Res. Treat. 4, 407-416 (2005).
67. Olivier JC, Huertas R, Lee HJ, Calon F, Pardridge WM. Synthesis of pegylated immunonanoparticles. Pharm. Res. 19, 1137-1143 (2002).
68. Gelperina SE, Khalansky AS, Skidan IN et al. Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicol. Lett. 126, 131-141 (2002).
69. Steininger SC, Kreuter J, Khalanskyi AS et al. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int. J. Cancer 109, 759-767 (2004).
70. Koziara JM, Lockman PR, Allen DD, Mumper RJ. Paclitaxel nanoparticles for the potential treatment of brain tumors. J. Control Release 99, 259-269 (2004).
71. Brigger I, Morizet J, Laudani L et al. Negative preclinical results with stealth nanospheres-encapsulated doxorubicin in an orthotopic murine brain tumor model. J. Control Release 100, 29-40 (2004).
72. Di Paolo A. Liposomal anticancer therapy: pharmacokinetic and clinical aspects. J. Chemother. 16, 90-93 (2004).
73. Fenske DB, Cullis PR. Entrapment of small molecules and nucleic acid-based drugs in liposomes. Methods Enzymol. 391, 7-40 (2005). Thorough review of liposomal technology.
74. Schnyder A, Huwyler J. Drug transport to brain with targeted liposomes. NeuroRx 2, 99-107 (2005).
75. Kshirsagar NA, Pandya SK, Kirodian BG, Sanath S. Liposomal drug delivery system from laboratory to clinic. J. Postgrad. Med. 51(Suppl. 1), S5-S15 (2005).
76. Ramsay EC, Dos Santos N, Dragowska WH, Laskin JJ, Bally MB. The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations. Curr. Drug Deliv. 2, 341-351 (2005).
77. Allen TM. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol. Sci. 15, 215-220 (1994).
78. Huwyler J, Wu D, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl Acad. Sci. USA 93, 14164-14169 (1996).
79. Zhang Y, Zhu C, Pardridge WM. Antisense gene therapy of brain cancer with an artificial virus gene delivery system. Mol. Ther. 6, 67-72 (2002).
80. Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB. The liposomal formulation of doxorubicin. Meth. Enzymol. 391, 71-97 (2005).
81. Allen TM, Martin FJ. Advantages of liposomal delivery systems for anthracyclines. Sem. in Oncol. 31, 5-15 (2004).
82. Vail DM, Amantea MA, Colbern GT, Martin FJ, Hilger RA, Working PK. Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. Sem. in Oncol. 31, 16-35 (2004).
83. Siegal T, Horowitz A, Gabizon A. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J. Neurosurg. 83, 1029-1037 (1995).
84. Sharma US, Sharma A, Chau RI, Straubinger RM. Liposome-mediated therapy of intracranial brain tumors in a rat model. Pharm. Res. 14, 992-998 (1997).
85. Saito R, Bringas JR, McKnight TR et al. Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res. 64, 2572-2579 (2004).
86. Koukourakis MI, Koukouraki S, Fezoulidis I et al. High intratumoral accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumors. Br. J. Cancer 83, 1281-1286 (2000).
87. Fabel K, Dietrich J, Hau P et al. Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer 92, 1936-1942 (2001).
88. Hau P, Fabel K, Baumgart U et al. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer 100, 1199-1207 (2004).
89. Chua SL, Rosenthal RA, Wong SS et al. Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme. Neuro-oncol. 6, 38-43 (2004).
90. Reszka RC, Jacobs A, Voges J. Liposome-mediated suicide gene therapy in humans. Methods Enzymol. 391, 200-208 (2005).
91. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc. Natl Acad. Sci. USA 91, 2076-2080 (1994).
92. Lieberman DM, Laske DW, Morrison PF, Bandiewicz KS, Oldfield EH. Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J. Neurosurg. 82, 1021-1029 (1995).
93. Mamot C, Nguyen JB, Pourdehnad M et al. Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery. J. Neuro-oncol. 68, 1-9 (2004).
94. Hall WA, Rustamzadeh E, Asher AL. Convection-enhanced delivery in clinical trials. Neurosurg. Focus 14, E2 (2003).
95. Hall WA, Scherr GT. Convection-enhanced delivery of targeted toxins for malignant glioma. Expert Opin. Drug Deliv. 3, 371-377 (2006).
96. Vandergrift WA, Patel SJ, Nicholas JS, Varma AK. Convection-enhanced delivery of immunotoxins and radioisotopes for treatment of malignant gliomas. Neurosurg. Focus 20, E13 (2006).
97. Chen MY, Chen ZJ, Gillies GT, Haar PJ, Broaddus WC. Intratumoral administration and convection-enhanced delivery. In: Handbook of Brain Tumor Chemotherapy. Newton HB (Ed.). Elsevier Medical Publishers - Academic Press, London, UK, 19, 295-304 (2006).
98. Brem H, Langer R. Polymer-based drug delivery to the brain. Science Med. 3, 2-11 (1996).
99. Raza SM, Pradilla G, Legnani FG et al. Local delivery of antineoplastic agents by controlled-release polymers for the treatment of malignant brain tumours. Expert Opin. Biol. Ther. 5, 477-494 (2005). Detailed review of the topic.
100. Haque RM, Amundson E, Dorsi M, Brem H. Interstitial chemotherapy and polymer-drug delivery. In: Handbook of Brain Tumor Chemotherapy. Newton HB (Ed.). Elsevier Medical Publishers - Academic Press, London, UK, 20, 274-294 (2006). Thorough overview of polymer-drug delivery.
101. Brem H, Piantadosi S, Burger PC et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery of biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-Brain Tumor Treatment Group. Lancet 345, 1008-1012 (1995).
102. Valtonen S, Timonen U, Toivanen P et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurg. 41, 44-48 (1997).
103. Westphal M, Hilt DC, Bortey E et al. A Phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol. 5, 79-88 (2003).
104. Sharma S, Nijdam AJ, Sinha PM et al. Controlled-release microchips. Expert Opin. Drug Deliv. 3, 379-394 (2006).
105. Meredith RF, LoBuglio AF. Recent progress in radioimmunotherapy of cancer. Oncology 11, 979-987 (1997).
106. Kalofonos HP, Pawlikowska TR, Hemingway A et al. Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase. J. Nucl. Med. 30, 1636-1645 (1989).
107. Riva P, Franceschi G, Arista A et al. Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas. A six-year clinical experience. Cancer 80, 2733-2742 (1997).
108. Bigner DD, Brown MT, Friedman AH et al. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: Phase I trial results. J. Clin. Oncol. 16, 2202-2212 (1998).
109. Cokgor I, Akabani G, Kuan CT et al. Phase trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J. Clin. Oncol. 18, 3862-3872 (2000).
110. 131I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J. Clin. Oncol. 20, 1389-1397 (2002).
111. Shapiro WR, Carpenter SP, Roberts K, Shan JS. (131)I-chTNT-1/B mAb: tumour necrosis therapy for malignant astrocytic glioma. Expert Opin. Biol. Ther. 6, 539-545 (2006).
112. Hall WA, Fodstad O. Immunotoxins and central nervous system neoplasia. J. Neurosurg. 76, 1-12 (1992).
113. Debinski W. Local treatment of brain tumors with targeted chimera cytotoxic proteins. Cancer Investig. 20, 801-809 (2002).
114. Cohen KA, Liu T, Bissonette R, Puri RK, Frankel AE. DAB389EGF fusion protein therapy of refractory glioblastoma multiforme. Curr. Pharm. Biotechnol. 4, 39-49 (2003).
115. Pastan I, Chaudhary VK, Fitzgerald D. Recombinant toxins as novel therapeutic agents. Ann. Rev. Biochem. 61, 331-354 (1992).
116. Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nature Med. 3, 1362-1368 (1997).
117. Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J. Neuro-oncol. 65, 3-13 (2003).
118. Sampson JH, Akabani G, Archer GE et al. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-α and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J. Neuro-Oncol. 65, 27-35 (2003).
119. Weber F, Asher A, Bucholz R et al. Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J. Neuro-oncol. 64, 125-137 (2003).
120. Weingart J, Tatter S, Rosenfeld S et al. Intratumoral convection-enhanced delivery of IL13-PE38QQR cytotoxin for recurrent malignant glioma without planned resection: a Phase I/II study. Neuro-oncol. 5, 357 (2003).
121. Prados M, Kunwar S, Lang FF et al. Final results of Phase I/II studies of IL13-PE38QQR administered intratumorally (IT) and/or peritumorally (PT) via convection-enhanced delivery (CED) in patients undergoing tumor resection for recurrent malignant glioma. Proc. Am. Soc. Clin. Oncol. 23, S115 (2005).
122. Gaillard PJ, Visser CC, de Boer AG. Targeted delivery across the blood-brain barrier. Expert Opin. Drug Deliv. 2, 299-309 (2005). Detailed review of targeted delivery.
123. Shin SU, Wu D, Ramanathan R, Pardridge WM, Morrison SL. Functional and pharmacokinetic properties of antibody/avidin fusion proteins. J. Immunol. 158, 4797-4804 (1997).
124. Friden PM, Walus LR, Musso GF, Taylor MA, Malfroy B, Starzyk RM. Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc. Natl Acad. Sci. USA 88, 4771-4775 (1991).
125. Pardridge WM, Buciak JL, Friden PM. Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. J. Pharmacol. Exp. Ther. 259, 66-70 (1991).
126. Coloma MJ, Lee HJ, Kurihara A et al. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm. Res. 17, 266-274 (2000).
127. Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development. Mol. Interven. 3, 90-105 (2003).